Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab
During the 2026 European Society for Medical Oncology (ESMO) Congress, first-line treatment options for patients with favorable-risk advanced renal cell carcinoma (RCC) attracted considerable attention. For this patient population, how to control disease while reducing the burden of long-term treatment remains an important question warranting further investigation. Oncology Frontier – UroStream invited Professor Jun Guo of Peking University Cancer Hospital to discuss the patient selection, dual-target blockade strategy, and potential clinical value of ivonescimab.









